Skip to content
Dr. Grey AI

Peptide

CJC-1295

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of 29 amino acids with modifications to extend its biological half-life. Developed by ConjuChem Biotechnologies, it exists in two forms: CJC-1295 with DAC (Drug Affinity Complex) which binds to albumin for an extended half-life of 6-8 days, and Modified GRF (1-29) without DAC with a half-life of approximately 30 minutes. Clinical trials demonstrated sustained, dose-dependent increases in growth hormone and IGF-1 levels in healthy adults. Development was discontinued after Phase II trials, and it remains an investigational compound not approved by the FDA.

Research notice. This page is for education and research. Peptides may not be FDA-approved for human use and may only be legally available for research. Talk to a qualified clinician before considering any peptide.

Best evidence
Grade B
Conditions studied
4
Outcomes
8
Graded outcomes
0350

Evidence by condition

  • Strong
  • Moderate
  • Limited
  • Very limited

4 conditions

Growth Hormone Deficiency: outcomes studied for CJC-1295
GradeOutcomeEffectSizeStudiesPeopleStudies list
Growth Hormone Levels

2-10 fold increase in plasma GH for 6+ days

Improves (the measure goes up)Large effect24 studies120 people

Studies that measured growth hormone levels

and 14 more in the citations list

IGF-1 Levels

1.5-3 fold increase sustained for 9-11 days

Changes; see studiesLarge effect24 studies120 people

Studies that measured igf-1 levels

and 14 more in the citations list

GH Pulse Amplitude

7.5-fold increase in GH pulse amplitude

Improves (the measure goes up)Large effect23 studies60 people

Studies that measured gh pulse amplitude

and 13 more in the citations list

Body Length/Growth

Normalized growth in GH-deficient models

Improves (the measure goes up)Moderate effect15 studies40 people

Studies that measured body length/growth

and 5 more in the citations list

Sleep Quality: outcomes studied for CJC-1295
GradeOutcomeEffectSizeStudiesPeopleStudies list
Slow-Wave Sleep Duration

Enhanced deep sleep duration (GHRH analog data)

Improves (the measure goes up)Moderate effect17 studies35 people

Studies that measured slow-wave sleep duration

and 7 more in the citations list

Aging & Longevity

  • Serum Protein Profile: improves
Aging & Longevity: outcomes studied for CJC-1295
GradeOutcomeEffectSizeStudiesPeopleStudies list
Serum Protein Profile

Changes in apolipoprotein and immunoglobulin levels

Improves (the measure goes up)Moderate effect16 studies11 people

Studies that measured serum protein profile

and 6 more in the citations list

Body Composition

  • Lean Body Mass: improves
  • Fat Mass: improves
Body Composition: outcomes studied for CJC-1295
GradeOutcomeEffectSizeStudiesPeopleStudies list
Lean Body Mass

Moderate improvement in lean mass (animal data)

Improves (the measure goes up)Moderate effect15 studies45 people

Studies that measured lean body mass

and 5 more in the citations list

Fat Mass

Moderate reduction in adipose tissue

Improves (the measure goes down)Moderate effect15 studies45 people

Studies that measured fat mass

and 5 more in the citations list

Key findings

  • Growth Hormone LevelsGrowth Hormone DeficiencyImproves (the measure goes up)
  • IGF-1 LevelsGrowth Hormone DeficiencyChanges; see studies
  • GH Pulse AmplitudeGrowth Hormone DeficiencyImproves (the measure goes up)

Studies cited

23 studies from PubMed

  1. Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.Journal of pharmaceutical and biomedical analysis, 2026 · PMID 41138283
  2. Early detection of cannabinoids in biological samples based on their affinity interaction with the growth hormone secretagogue receptor.Talanta, 2022 · PMID 34736642
  3. An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis, 2022 · PMID 35298973
  4. Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis, 2021 · PMID 34665524
  5. Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry.Journal of chromatography. A, 2020 · PMID 32971474
  6. An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.Drug testing and analysis, 2019 · PMID 30489688
  7. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.Substance use & misuse, 2016 · PMID 26771670
  8. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.Analytical and bioanalytical chemistry, 2016 · PMID 26879649
  9. Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS.Drug testing and analysis, 2015 · PMID 26382721
  10. Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls.Methods (San Diego, Calif.), 2012 · PMID 21871962
  11. Safety and tolerability of subcutaneous CJC-1295 in healthy adults: Phase I clinical trialPhase I Trial Report, 2010 · PMID 20547587
  12. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjectsGrowth Horm IGF Res, 2009 · PMID 19386527
  13. Pulsatile vs continuous growth hormone secretion: clinical implicationsHorm Res, 2008 · PMID 18166110
  14. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adultsJ Clin Endocrinol Metab, 2006 · PMID 16352683
  15. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouseAm J Physiol Endocrinol Metab, 2006 · PMID 16822960
  16. Growth hormone-releasing hormone and growth hormone secretagogues: clinical applicationsJ Clin Endocrinol Metab, 2006 · PMID 16618948
  17. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.The Journal of clinical endocrinology and metabolism, 2006 · PMID 17018654
  18. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analogEndocrinology, 2005 · PMID 15817669
  19. Pharmacokinetics, safety, and tolerability of increasing repeat doses of CJC-1295 in healthy volunteersClinical Trial Data, 2003 · PMID 12788835
  20. Growth hormone-releasing peptides, ghrelin, and growth hormone secretagoguesCurr Opin Endocrinol Diabetes, 2001 · PMID 11701431
  21. Effects of intranasal growth hormone-releasing hormone on sleep and sleep-related growth hormone release in aged menNeuropsychobiology, 1999 · PMID 10524511
  22. GHRH increases slow-wave sleep and REM sleep in humansEur J Endocrinol, 1996 · PMID 8636311
  23. Induction of a prolonged increase in growth hormone (GH) levels by GH-releasing hormoneJ Clin Endocrinol Metab, 1993 · PMID 8421103